TASSINARI, ELISA
 Distribuzione geografica
Continente #
AS - Asia 197
EU - Europa 196
NA - Nord America 182
AF - Africa 13
Totale 588
Nazione #
US - Stati Uniti d'America 180
SG - Singapore 114
IT - Italia 101
CN - Cina 53
SE - Svezia 16
FI - Finlandia 15
CH - Svizzera 14
CI - Costa d'Avorio 13
IE - Irlanda 12
JO - Giordania 12
BG - Bulgaria 11
IN - India 8
NL - Olanda 8
DE - Germania 7
ID - Indonesia 5
FR - Francia 3
GB - Regno Unito 3
RU - Federazione Russa 3
CA - Canada 2
HK - Hong Kong 2
PK - Pakistan 2
PL - Polonia 2
AT - Austria 1
JP - Giappone 1
Totale 588
Città #
Singapore 104
Santa Clara 50
Bologna 31
Boardman 29
Ashburn 15
Abidjan 13
Amman 12
Bern 12
Dublin 12
Helsinki 11
Sofia 11
Guangzhou 10
Milan 10
Hyderabad 8
Jakarta 5
Turin 5
Falkenstein 4
Lappeenranta 4
Rimini 4
Beijing 3
Columbus 3
Enschede 3
Munich 3
Paris 3
Rome 3
Telgate 3
Cagliari 2
Chengdu 2
Florence 2
Gatineau 2
Genoa 2
Gujrat 2
Hong Kong 2
Legnano 2
Modena 2
Moscow 2
Nanjing 2
Perugia 2
Shanghai 2
Slough 2
Verona 2
Warsaw 2
Zhengzhou 2
Amsterdam 1
Bari 1
Fort Worth 1
Fuzhou 1
Hangzhou 1
Jiaozuo 1
Jinan 1
Jinhua 1
Leicester 1
Lugano 1
Nanning 1
Oderzo 1
Ravenna 1
Reinach 1
Seattle 1
Shenzhen 1
Shijiazhuang 1
Taizhou 1
Tianjin 1
Tokyo 1
Trento 1
Vienna 1
Wenzhou 1
Xi'an 1
Zhoukou 1
Totale 430
Nome #
The Palliative Prognostic (PaP) Score without Clinical Evaluation Predicts Early Mortality among Advanced NSCLC Patients Treated with Immunotherapy 51
A hypothesis-generating analysis on the role of TERT promoter mutation in advanced urothelial carcinoma treated with immunotherapy 38
Hypertransaminasemia in metastatic renal cell carcinoma patients receiving immune-based combinations: a meta-analysis 37
Bone Targeting Agents in Patients with Prostate Cancer: General Toxicities and Osteonecrosis of the Jaw 36
Chromosome 3p gene alterations as biomarkers for immunocombinations in metastatic renal cell carcinoma: A hypothesis-generating analysis 36
Prognostic Factors of Survival for High-Grade Neuroendocrine Neoplasia of the Bladder: A SEER Database Analysis 36
A prospective study on the early evaluation of response to androgen receptor-targeted agents with 11C-Choline, 68Ga-PSMA, and 18F-FACBC PET in metastatic castration-resistant prostate cancer: a single-center experience 36
Adjuvant PD-1 and PD-L1 Inhibitors and Relapse-Free Survival in Cancer Patients: The MOUSEION-04 Study 34
Tumor growth rate to assess therapy response to immune-based combinations for metastatic renal cell carcinoma 32
Implications of TERT promoter mutations and telomerase activity in solid tumors with a focus on genitourinary cancers 30
Metabolic pseudoprogression in a patient with metastatic KIT exon 11 GIST after 1 month of first-line imatinib: a case report 27
The impact of ECOG performance status on efficacy of immunotherapy and immune-based combinations in cancer patients: the MOUSEION-06 study 27
Guiding treatment selection with immunotherapy compared to targeted therapy agents in patients with metastatic kidney cancer 26
Treatment Options for Metastatic Urothelial Carcinoma After First-Line Chemotherapy 25
Hypertransaminasemia in cancer patients receiving immunotherapy and immune-based combinations: the MOUSEION-05 study 23
TERT promoter mutations and the outcome of patients with advanced urothelial carcinoma treated by platinum-based chemotherapy or pembrolizumab 22
Appropriateness of Mini-Invasive Approaches for Nausea and Vomiting Refractory to Medical Therapy in Palliative Care Setting: A Case Report 21
How Do Molecular Classifications Affect the Neoadjuvant Treatment of Muscle-Invasive Urothelial Carcinoma? 17
Do we need alternative PD-1 inhibitors for the treatment of renal cell carcinoma? 15
Complete remissions following immunotherapy or immuno-oncology combinations in cancer patients: the MOUSEION-03 meta-analysis 15
An update on safety evaluation of immune-based combinations in patients with advanced renal cell carcinoma 14
Prostate cancer and novel pharmacological treatment options - what's new for 2022? 13
What is the risk of hepatotoxicity induced by immune-checkpoint inhibitors and how can we avoid it? 10
Re: Atezolizumab Plus Cabozantinib Versus Cabozantinib Monotherapy for Patients with Renal Cell Carcinoma After Progression with Previous Immune Checkpoint Inhibitor Treatment (CONTACT-03): A Multicentre, Randomised, Open-label, Phase 3 Trial 9
Novel Immune Checkpoint Inhibitor Targets in Advanced or Metastatic Renal Cell Carcinoma: State of the Art and Future Perspectives 9
Totale 639
Categoria #
all - tutte 3.042
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 3.042


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2022/2023137 0 0 0 0 14 3 8 5 39 11 25 32
2023/2024155 10 18 13 8 14 29 4 15 11 5 18 10
2024/2025347 44 85 60 49 80 29 0 0 0 0 0 0
Totale 639